文献速递临床试验与 GCP

高心脏风险患者术后限制性或开放性输血:TOP随机临床试验

Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

TOP试验为平行、单盲、随机临床优效性试验,纳入1428名接受大血管或普通外科手术的高心脏风险退伍军人,随机分为开放性输血策略(血红蛋白<10 g/dL触发)与限制性策略(血红蛋白<7 g/dL触发)。主要终点为90天内全因死亡、心肌梗死、冠状动脉血运重建、急性肾衰竭或缺血性卒中的复合终点,开放性组9.1% vs 限制性组10.1%(相对风险0.90;95%CI 0.65-1.24)。结论:开放性输血策略未降低90天死亡或主要缺血结局发生率。

要点

  • 高心脏风险患者大手术后,开放性输血策略(血红蛋白<10 g/dL触发)未降低90天死亡或主要缺血结局。
  • 主要终点发生率开放性组9.1%(61/670)vs 限制性组10.1%(71/700),相对风险0.90(95%CI 0.65-1.24)。
  • 心肌梗死以外的心脏并发症(5个次要终点之一)开放性组5.9%(38/647)vs 限制性组9.9%(67/678),相对风险0.59(99%CI 0.36-0.98)。

核心结论

  • 在高心脏风险患者接受大血管或普通外科手术后,与限制性输血策略相比,开放性输血策略未降低90天死亡或主要缺血结局发生率。

研究设计与样本

  • 平行、单盲、随机临床优效性试验,纳入1428名≥18岁高心脏风险退伍军人,2018年2月至2023年3月在美国16个退伍军人事务医疗中心入组。
  • 714名术后血红蛋白<10 g/dL的参与者随机分配至开放性策略(血红蛋白<10 g/dL触发输血),714名分配至限制性策略(血红蛋白<7 g/dL触发输血)。

主要发现

  • 1424名可分析退伍军人中,平均年龄69.9岁(SD 7.9),1393名男性(97.8%),268名黑人(18.8%),48名西班牙裔(4.1%),1071名白人(75.2%);1297名(91.1%)接受血管外科手术。
  • 随机化后第5天,两种输血策略间平均血红蛋白差异为2.0 g/dL。
  • 主要终点(90天内全因死亡、心肌梗死、冠状动脉血运重建、急性肾衰竭或缺血性卒中的复合终点)发生率开放性组9.1%(61/670)vs 限制性组10.1%(71/700),相对风险0.90(95%CI 0.65-1.24)。
  • 心肌梗死以外的心脏并发症(5个次要终点之一)发生率开放性组5.9%(38/647)vs 限制性组9.9%(67/678),相对风险0.59(99%CI 0.36-0.98)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Postoperative red blood cell transfusion guidelines recommend transfusion for hemoglobin levels less than 7 g/dL. However, the safety of this strategy in patients at high risk of cardiac events undergoing major operations remains unclear. OBJECTIVE: To evaluate the risk of death or major ischemic events within 90 days after a liberal transfusion strategy compared with a restrictive transfusion strategy in patients at high risk of cardiac events who had undergone major vascular or general surgery operations and developed postoperative anemia. DESIGN, SETTING, AND PARTICIPANTS: This parallel, single-blind, randomized clinical superiority trial included 1428 veterans (≥18 y) at high cardiac risk undergoing major vascular or general surgery operations. Participants were enrolled from February 2018 to March 2023 across 16 Veterans Affairs Medical Centers in the US. INTERVENTIONS: Seven hundred fourteen participants with postoperative hemoglobin less than 10 g/dL were randomized to a liberal strategy (transfusion trigger at hemoglobin level <10 g/dL) and 714 to a restrictive strategy (transfusion trigger at hemoglobin <7 g/dL). MAIN OUTCOMES AND MEASURES: The primary end point was a composite of all-cause death, myocardial infarction, coronary revascularization, acute kidney failure, or ischemic stroke within 90 days after randomization. Secondary end points included a composite of cardiac complications other than myocardial infarction (arrhythmias, heart failure, and nonfatal cardiac arrest). RESULTS: Of the 1424 analyzed veterans (mean age, 69.9 [SD, 7.9] years; 1393 male [97.8%]; 268 Black [18.8%]; 48 Hispanic [4.1%]; 1071 White [75.2%]), 1297 (91.1%) underwent vascular surgical procedures. The mean hemoglobin difference between transfusion strategies was 2.0 g/dL on day 5 after randomization. The primary outcome rate in the liberal group was 9.1% (61 of 670) compared with 10.1% (71 of 700) in the restrictive group (relative risk, 0.90; 95% CI, 0.65-1.24). The secondary end point of cardiac complications without myocardial infarction, which was 1 of 5 secondary end points, occurred in 5.9% (38 of 647) of patients in the liberal group and 9.9% (67 of 678) of patients in the restrictive group (relative risk, 0.59; 99% CI, 0.36-0.98). CONCLUSIONS AND RELEVANCE: After major vascular or general surgery operations among patients at high risk of a cardiac event, a liberal transfusion strategy did not reduce 90-day death or major ischemic outcome rates compared with a restrictive strategy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03229941.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Kougias P, Sharath SE, Zhan M, et al. Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial. JAMA. 2025. PMID: 41205227. doi:10.1001/jama.2025.20841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。